Julio Rosenstock, director of the Dallas Diabetes Research Center, expanded on the results of tirzepatide, explaining that the SURPASS-3 trial showed that it leads to greater time in range
Overexpression of IRP2 or MPP + treatment significantly enhances the binding of IRP2 to p53 in PC-12 cells, upregulates p53 levels, downregulates SLC7A11 expression, and increases arachidonate 12-Lipoxygenase (ALOX12) expression, thereby promoting ferroptosis and amino acid antioxidant system disruptions, elevating MDA levels, and inducing PC-12 cell damage
Outcome Focus: The trials were designed primarily to assess weight loss efficacy, with safety as a secondary outcome
Take a pea-sized amount of the cream on your fingertips
[PMID: 7144747] PubMed record related to this compound for laboratory literature review
Skin Whitening Creams & Serums: Work externally and take longer to show visible changes